Role of ADCs in HER2-Mutated NSCLC

Opinion
Video

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Related Videos
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Ibrahim Aldoss, MD
D. Ross Camidge, MD, PhD
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
D. Ross Camidge, MD, PhD
Related Content
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024
Podcast
Lung Cancer

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024
Article
Diane M. Simeone, MD; Marwan G. Fakih, MD

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023
Podcast
Maurie Markman, MD

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate

May 9th 2024
Article
Andrew Joe, MD

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024
Article